Search results
Results from the WOW.Com Content Network
The IO route of fluid and medication administration is an alternative to the preferred intravascular route when the latter cannot be established promptly in emergent situations. Intraosseous infusions are used when people have compromised intravenous access and need immediate delivery of life-saving fluids and medications.
Abaloparatide, sold under the brand name Tymlos among others, is a parathyroid hormone-related protein (PTHrP) analog medication used to treat osteoporosis. [1] It is an anabolic (i.e., bone growing) agent.
Infusion therapy involves the administration of medication through a needle or catheter. Typically, "infusion therapy" means that a drug is administered intravenously or subcutaneously. The term may pertain where drugs are provided through other non-oral routes of administration , such as intramuscular injection and epidural administration ...
V-Set: Multiple line IV injection site whereby several lines can be used at the same time for administering drugs to the patient.. In intravenous therapy a Y-Set, T-Set and V-Sets are Y-, T- and V-shaped three-way connector sets made of connecting plastic tubes used for delivering intravenous drugs into the body from multiple fluid sources.
In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate. If these are ineffective or if the person develops digestive tract problems, intravenous pamidronate may be used. Strontium ranelate or teriparatide are used for refractory disease.
Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein.The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not—due to reduced mental states or otherwise—consume food or water by mouth.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]